Saioa Arza-Apalategi

Ms. Saioa Arza-Apalategi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
BHBranco Heuts
Branco Heuts
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
SASinne Alkema
Sinne Alkema
ETEsther Tijchon
Esther Tijchon
LJLaura Jussen
Laura Jussen
JMJ. H. A. Martens
J. H. A. Martens
A t(9;11)(p22;q23) translocation produces the MLL-AF9 fusion protein, which is found in up to 25% of de novo AML cases in children. Despite major advances, obtaining a comprehensive understanding of context-dependent MLL-AF9-mediated gene programs during early hematopoiesis is challenging. Here, we generated a human inducible pluripotent stem cell (hiPSC) model with a doxycycline dose-dependent MLL-AF9 expression. We exploited MLL-AF9 expression as an oncogenic hit to uncover epigenetic and transcriptomic effects on iPSC-derived hematopoietic development and the transformation into (pre-)leukemic states. In doing so, we observed a disruption in early myelomonocytic development. Accordingly, we identified gene profiles that were consistent with primary MLL-AF9 AML and uncovered high-confidence MLL-AF9-associated core genes that are faithfully represented in primary MLL-AF9 AML, including known and presently unknown factors. Using single-cell RNA-sequencing, we identified an increase of CD34 expressing early hematopoietic progenitor-like cell states as well as granulocyte-monocyte progenitor-like cells upon MLL-AF9 activation. Our system allows for careful chemically controlled and stepwise in vitro hiPSC-derived differentiation under serum-free and feeder-free conditions. For a disease that currently lacks effective precision medicine, our system provides a novel entry-point into exploring potential novel targets for personalized therapeutic strategies.

18 February 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
BHBranco M. H. Heuts
Branco M. H. Heuts
MDMeike T. M. Dooijes
Meike T. M. Dooijes
DGDaan Gilissen
Daan Gilissen
AHAdrian J. P. van der Heijden
Adrian J. P. van der Heijden
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden

4 December 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
BHBranco M. H. Heuts
Branco M. H. Heuts
SBSaskia M. Bergevoet
Saskia M. Bergevoet
RMRoos Meering
Roos Meering
DGDaan Gilissen
Daan Gilissen
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden

2 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
BHBranco Heuts
Branco Heuts
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
SASinna Alkema
Sinna Alkema
ETEsther Tijchon
Esther Tijchon
LJLaura Jussen
Laura Jussen
JMJ. H. A. Martens
J. H. A. Martens
A t(9;11)(p22;q23) translocation produces the MLL-AF9 fusion protein, which is found in up to 25% of de novo AML cases in children. Despite major advances, obtaining a comprehensive understanding of context-dependent MLL-AF9-mediated gene programs during early hematopoiesis is challenging. Here, we generated a human inducible pluripotent stem cell (hiPSC) model with doxycycline dose-dependent MLL-AF9 expression. We exploit MLL-AF9 expression as an oncogenic hit to uncover epigenetic and transcriptomic effects on iPSC-derived hematopoietic development and the transformation into (pre-)leukemic states. In doing so, we observed disruption of early myelomonocytic development and expansion of a CD34+ early hematopoietic progenitor compartment upon MLL-AF9 activation. In agreement, we identified gene profiles consistent with primary MLL-AF9 AML and uncovered highly confident MLL-AF9-associated core genes that faithfully represent primary MLL-AF9 AML, including known and thus far unknown factors. Our system allows for careful chemically controlled and stepwise in vitro hiPSC-derived differentiation under serum-free and feeder-free conditions. For a disease that currently lacks effective precision medicine, our system provides a novel entry-point into exploring potential novel biomarkers and targets for personalized therapeutic strategies.

27 May 2026 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
SASaioa Arza-Apalategi
Saioa Arza-Apalategi
DGDaan Gilissen
Daan Gilissen
AGAnne C van der Grinten
Anne C van der Grinten
SOSeline Natalie Van den Oever
Seline Natalie Van den Oever
EAErik van den Akker
Erik van den Akker
BRB. A. van der Van der Reijden
B. A. van der Van der Reijden
Background/Objectives: Acute myeloid leukemia (AML) comprises genetic subclasses with distinct gene expression profiles. While AML gene expression studies have mainly focused on protein-coding genes, our understanding of expression patterns of long intergenic noncoding RNAs (lincRNAs) remains incomplete. This is due to limited sample sizes, as well as incomplete annotation of lncRNAs with context-dependent expression. Methods: To address this gap, we developed the bioinformatic pipeline LIRA (long intergenic noncoding RNA annotator) to identify novel lincRNAs using stringent criteria, including spliced and intergenic transcripts, and algorithms to exclude coding potential. Results: By applying LIRA to RNA-sequencing data from 878 pediatric and adult AML cases and 20 healthy controls, we identified 1560 novel lincRNAs, expanding the GENCODE v38 lincRNA catalog by 27%. Integration of in-house-generated CAGE- and ChIP-sequencing data from KMT2A::MLLT3 samples revealed that 80% of the novel lincRNAs are 5′ capped, and at least 67% harbor activating epigenetic marks at their transcription start sites. Unsupervised analysis of the 1000 most variable known and newly identified lincRNAs uncovered subclass-specific expression patterns, mirroring those observed for protein-coding genes. Weighted Gene Co-expression Network Analysis identified 17 lincRNA expression modules associated with AML subclasses. Notably, expression of these modules decreased upon degradation of the leukemogenic onco-fusion proteins KMT2A::MLLT3 and PML::RARA, indicating that lincRNA expression is responsive to oncogenic signaling. Conclusions: This comprehensive analysis shows that lincRNAs exhibit similar subclass-specific expression patterns as protein-coding genes and establishes a valuable resource for future studies on genetically defined AML subclasses, with potential implications for biomarker discovery and therapeutic targeting.